| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909184 | Leukemia Research | 2012 | 5 Pages |
Abstract
No series have reported the results of the use of the therapeutic anti-CD20 monoclonal antibody (Rituximab) in the setting of adult refractory/relapsed B-ALL. We report here the outcomes of such nine patients treated at two french institutions by a combination of Rituximab + chemotherapy. We showed that four patients could achieve complete response while four other patients were documented with blast clearance superior to 50% from the baseline in bone marrow. We conclude that our results suggested some efficacy for the use of Rituximab in combination with chemotherapy in the setting of refractory/relapsed adult B-ALL. Larger series within prospective trials are needed to confirm these results.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Patrice Chevallier, Arnaud Pigneux, Nelly Robillard, Sameh Ayari, Thierry Guillaume, Jacques Delaunay, Marion Eveillard, Pierre-Yves Dumas, Eric Lippert, Mohamad Mohty, Thibaut Leguay,